1 – 10 of 27
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Retrospective evaluation of the predictive value of tumour burden at baseline [
68 Ga]Ga-DOTA-TOC or -TATE PET/CT and tumour dosimetry in GEP-NET patients treated with PRRT.
(
- Contribution to journal › Article
-
Mark
Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE
(
- Contribution to journal › Article
- 2022
-
Mark
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
(
- Contribution to journal › Article
-
Mark
Dosimetric quantities of neuroendocrine tumors over treatment cycles with 177Lu-DOTA-TATE
(
- Contribution to journal › Article
- 2021
-
Mark
Peptide Receptor Radionuclide Therapy – Prospects for Personalised Treatment
(
- Contribution to journal › Article
-
Mark
EANM dosimetry committee series on standard operational procedures : a unified methodology for 99mTc-MAA pre- and 90Y peri-therapy dosimetry in liver radioembolization with 90Y microspheres
(
- Contribution to journal › Article
- 2019
-
Mark
Re : Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma
(
- Contribution to journal › Letter
- 2018
-
Mark
A method for tumor dosimetry based on hybrid planar-SPECT/CT images and semiautomatic segmentation
(
- Contribution to journal › Article
-
Mark
3-D Image-Based Dosimetry in Radionuclide Therapy
(
- Contribution to journal › Scientific review
- 2017
-
Mark
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
(
- Contribution to journal › Article